Genespire raises $52m in Series B to trial paediatric gene therapy
The funds will advance Genespire’s gene therapy for methylmalonic acidemia, a group of rare metabolic disorders, to Phase I/II trials.
Cell & Gene Therapy
Q2 2024 update: cell & gene therapy related hiring actvity in the pharma industry
APAC leaps ahead in adoptive cell therapy space
Anti-obesity drugs will be 2024’s defining trend
Influx of adoptive cell therapies may be on the horizon
Q3 2023 update: cell & gene therapy related hiring actvity in the pharma industry
